SCHEMBL5496965

SCHEMBL5496965

COc1c(C#N)cccc1-c1ccc(N)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ PLA2G7 Q13093 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ GSK3A P49840 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ DYRK1A Q13627 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37
▸ MAPT P10636 3/20 0.36
▸ GAA P10253 2/20 0.36
▸ GLA P06280 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CYP3A4 P08684 4/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27659861 0.73 L3MBTL1 (0.44) KDM4EALDH1A1L3MBTL1DYRK1AMAPT
SCHEMBL20400253 0.72 HSP90AA1 (0.58) KDM4EL3MBTL1GSK3AGSK3BDYRK1A
SCHEMBL30401919 0.72 HSP90AA1 (0.58) KDM4EL3MBTL1GSK3AGSK3BDYRK1A
SCHEMBL6736896 0.71 POLB (0.47) KDM4EALDH1A1USP2MAPTGAA
SCHEMBL25027218 0.71 KDM4E (0.49) KDM4EALDH1A1USP2L3MBTL1GSK3A
SCHEMBL30204941 0.70 ALDH1A1 (0.43) KDM4EALDH1A1USP2L3MBTL1MAPT
SCHEMBL15689602 0.70 ALDH1A1 (0.43) KDM4EALDH1A1USP2L3MBTL1MAPT
SCHEMBL22315720 0.70 L3MBTL1 (0.46) KDM4EALDH1A1L3MBTL1DYRK1AMAPT
SCHEMBL16428785 0.69 MAOA (0.47) KDM4EALDH1A1MAPTGAANPC1
SCHEMBL5502501 0.69 PGR (0.45) KDM4EALDH1A1L3MBTL1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INC. 2007-11-01 — — US disclosed
EP-1778233-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 2007-05-02 — — EP disclosed
WO-2006019716-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS CASR, GRK2, RYR2 KDM4E 4073/4885ALDH1A1 4580/4885USP2 3506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback